2cureX decides on rights issue prior to market launch of IndiTreat®
2cureX AB ("2cureX") today announces that the Board of Directors, with the support of the authorisation from the Extraordinary General Meeting on April 2nd, 2019, has decided to conduct a rights issue of shares that can provide a maximum of approximately SEK 24.7 million to the company before issue costs. The general public is also invited to subscribe for shares in the rights issue. The rights issue is conducted with the purpose of financing pre-launch and market launch of IndiTreat®, completion of ongoing clinical validation studies and establishment of additional commercial testing centers